Ингибирование экспрессии онкогенов семейства myc и пролиферации опухолевых клеток человека с помощью двуцепочечных интерферирующих РНК
Диссертация
Двуцепочечные РНК рассматриваются как перспективные препараты для применения в терапии, благодаря их уникальной способности запускать в клетках процесс РНК-интерференции, приводящий к специфической деградации мРНК гомологичных им генов. Выбор высокоэффективных siPHK, направленных на подавление экспрессии как гена с-тус, так и N-myc, позволит использовать их для ингибирования пролиферации разных… Читать ещё >
Список литературы
- Uppman S.M., Glisson B.S., Kavanagh J.J., Lotan R., Hong W.K., Paredes-Espinoza M., Hittelman W.N., Holdener E.E., Krakoff I.H. Retinoic acid and interferon combination studies in human cancer// Eur. J. Cancer 1993. V. 29A Suppl 5 P. S9−13
- Reynolds C.P., Wang Y., Melton L.J., Einhorn P.A., Slamon D.J., Maurer B.J. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide// Med. Pediatr. Oncol. 2000. V. 35 P. 597−602
- Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons II Annu. Rev. Biochem. 1998. V. 67 P. 227−264
- Kimchi A. Cytokine triggered molecular pathways that control cell cycle arrest II J. Cell Biochem. 1992. V. 50 P. 1−9
- Sawyers C. Targeted cancer therapy // Nature 2004. V. 432 P. 294−297
- Emens L.A. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer //Am. J. Ther. 2005. V. 12 P. 243−253
- Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy // N. Engl. J. Med. 2005. V. 353 P. 172−187
- DePinho R.A., Schreiber-Agus N. Alt F.W. myc family oncogenes in the development of normal and neoplastic ceils//Adv. Cancer Res. 1991. V. 57 P. 1−46
- Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism // Mol. Cell Biol. 1999. V. 19 P. 1−11
- Resar L.M., Dolde C., Barrett J.F., Dang C.V. B-myc inhibits neoplastic transformation and transcriptional activation by c-myc// Mol. Cell Biol. 1993. V. 13 P. 1130−1136
- Asai A., Miyagi Y., Sugiyama A., Nagashima Y., Kanemitsu H., Obinata M., Mishima K, Kuchino Y. The s-Myc protein having the ability to induce apoptosis is selectively expressed in rat embryo chondrocytes // Oncogene 1994. V. 9 P. 2345−2352
- Sugiyama A., Noguchi K., Kitanaka C., Katou N. Tashiro F., Ono Т., Yoshida M.C., Kuchino Y. Molecular cloning and chromosomal mapping of mouse intronless myc gene acting as a potent apoptosis inducer // Gene 1999. V. 226 P. 273−283
- Heikkila R., Schwab G., Wickstrom E., Loke S.L., Pluznik D.H., Watt R., Neckers L.M. A c-myc antisense oligodeoxynucieotide inhibits entry into S phase but not progress from GO to G1 // Nature 1987. V. 328 P. 445−449
- Eilers M., Picard D., Yamamoto K.R., Bishop J.M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells // Nature 1989. V. 340 P. 66−68
- Roussel M.F. Key effectors of signal transduction and G1 progression II Adv. Cancer Res. 1998. V. 74 P. 1−24
- Adachi S., Obaya A.J., Han Z., Ramos-Desimone N. Wyche J.H., Sedivy J.M. c-Myc is necessary for DNA damage-induced apoptosis in the G (2) phase of the cell cycle // Mol. Cell Biol. 2001. V. 21 P. 4929−4937
- Dani C., Blanchard J.M., Piechaczyk M., El S.S., Marty L., Jeanteur P. Extreme instability of myc mRNA in normal and transformed human cells // Proc. Natl. Acad. Sci U. S. A 1984. V. 81 P. 7046−7050
- Hann S.R., Eisenman R.N. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells // Mol. Cell Biol. 1984. V. 4 P. 2486−2497
- Ramsay G., Evan G.I., Bishop J.M. The protein encoded by the human proto-oncogene c-myc // Proc. Natl. Acad. Sci. U. S. A 1984. V. 81 P. 7742−7746
- Oster S.K., Ho C.S., Soucie E.L., Penn L.Z. The myc oncogene: MarvelouslY Complex II Adv. Cancer Res. 2002. V. 84 P. 81−154
- Cole M.D. The myc oncogene: its role in transformation and differentiation // Annu. Rev. Genet. 1986. V. 20 P. 361−384
- Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease // Oncogene 1999. V. 18 P. 3004−3016
- Boxer L.M., Dang C.V. Translocations involving c-myc and c-myc function // Oncogene 2001. V. 20 P. 5595−5610
- Prochownik E.V. c-Myc as a therapeutic target in cancer // Expert. Rev. Anticancer Ther. 2004. V. 4 P. 289−302
- Schwab M. MYCN in neuronal tumours // Cancer Lett. 2004. V. 204 P. 179−187
- Thomas W.D., Raif A., Hansford L., Marshall G. N-myc transcription molecule and oncoprotein II Int. J. Biochem. Cell Biol. 2004. V. 36 P. 771−775
- Lee W.H., Murphree A.L., Benedict W.F. Expression and amplification of the N-myc gene in primary retinoblastoma // Nature 1984. V. 309 P. 458−460
- Garson J.A., Mclntyre P.G., Kemshead J.T. N-myc amplification in malignant astrocytoma // Lancet 1985. V. 2 P. 718−719
- Collins V.P. Amplified genes in human gliomas // Semin. Cancer Biol. 1993. V. 4 P. 2732
- Hui А.В., Lo K.W., Yin X.L., Poon W.S., Ng H.K. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization // Lab Invest 2001. V. 81 P. 717−723
- Wu R., Lin L., Beer D.G., Ellenson L.H., Lamb B.J., Rouillard J.M., Kuick R., Hanash S., Schwartz D.R., Fearon E.R., Cho K.R. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas//Am. J. Pathol. 2003. V. 162 P. 1603−1610
- Bernasconi N.L., Wormhoudt T.A., Laird-Offringa I.A. Post-transcriptional deregulation of myc genes in lung cancer cell lines // Am. J. Respir. Cell Mol. Biol. 2000. V. 23 P. 560 565
- Ponzielli R., Katz S., Barsyte-Lovejoy D.(Penn L.Z. Cancer therapeutics: targeting the dark side of Мус // Eur. J. Cancer 2005. V. 41 P. 2485−2501
- Hoffman В., Amanullah A., Shafarenko M., Liebermann D.A. The proto-oncogene c-myc in hematopoietic development and leukemogenesis // Oncogene 2002. V. 21 P. 34 143 421
- Mai S., Mushinski J.F. c-Myc-induced genomic instability // J. Environ. Pathol. Toxicol. Oncol. 2003. V. 22 P. 179−199
- Nilsson J.A., Cleveland J.L. Мус pathways provoking cell suicide and cancer // Oncogene 2003. V. 22 P. 9007−9021
- Ruddell A., Mezquita P., Brandvold K.A., Farr A., Iritani B.M. В lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis // Am. J. Pathol. 2003. V. 163 P. 2233−2245
- Flores I., Murphy D.J., Swigart L.B., Knies U., Evan G.I. Defining the temporal requirements for Мус in the progression and maintenance of skin neoplasia // Oncogene 2004. V. 23 P. 5923−5930
- Schmidt E.V. The role of c-myc in regulation of translation initiation // Oncogene 2004. V. 23 P. 3217−3221
- Blakely C.M., Sintasath L. D’Cruz C.M., Hahn K.T., Dugan K.D., Belka G.K., Chodosh L.A. Developmental stage determines the effects of MYC in the mammary epithelium // Development 2005. V. 132 P. 1147−1160
- Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network // Gene 2001. V. 277 P. 1−14
- Kato G.J., Barrett J., Villa-Garcia M., Dang C.V. An amino-terminal c-myc domain required for neoplastic transformation activates transcription // Mol. Ceil Biol. 1990. V. 10 P. 5914−5920
- Baxevanis A.D., Vinson C.R. Interactions of coiled coils in transcription factors: where is the specificity?// Curr.Opin. Genet. Dev. 1993. V. 3 P. 278−285
- Blackwell Т.К., Kretzner L., Blackwood EM, Eisenman R.N., Weintraub H. Sequence-specific DNA binding by the c-Myc protein // Science 1990. V. 250 P. 1149−1151
- Herbst A., Hemann M.T., Tworkowski K.A., Salghetti S.E., Lowe S.W., Tansey W.P. A conserved element in Мус that negatively regulates its proapoptotic activity II EMBO Rep. 2005. V. 6 P. 177−183
- McEwan I.J., hlman-Wright K., Ford J., Wright A.P. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding II Biochemistry 1996. V. 35 P. 9584−9593
- Fladvad M., Zhou K., Moshref A., Pursglove S., Safsten P., Sunnerhagen M. N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding // J. Mol. Biol. 2005. V. 346 P. 175−189
- Mukherjee В., Morgenbesser S.D., DePinho R.A. Мус family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants II Genes Dev. 1992. V. 6 P. 1480−1492
- Amati В., Brooks M.W., Levy N. Littlewood T.D., Evan G.I., Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max II Cell 1993. V. 72 P. 233−245
- Nair S.K., Burley S.K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors II Cell 2003. V. 112 P. 193−205
- Galaktionov K" Chen X., Beach O. Cdc25 cell-cycle phosphatase as a target of c-myc // Nature 1996. V. 382 P. 511−517
- Wu S., Pena A., Korcz A., Soprano D.R., Soprano K.J. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex//Oncogene 1996. V. 12 P. 621−629
- Facchini L.M., Penn L.Z. The molecular role of Мус in growth and transformation: recent discoveries lead to new insights // FASEB J. 1998. V. 12 P. 633−651
- Amati В., Dalton S., Brooks M.W., Littlewood T.D., Evan G.I., Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max // Nature 1992. V. 359 P. 423−426
- Gu W., Cechova K., Tassi V., la-Favera R. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max // Proc. Natl. Acad. Sci. U. S. A1993. V. 90 P. 29 352 939
- Ayer D.E., Kretzner L., Eisenman R.N. Mad: a heterodimeric partner for Max that antagonizes Мус transcriptional activity// Cell 1993. V. 72 P. 211−222
- Zervos A.S., Gyuris J., Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites // Cell 1993. V. 72 P. 223−232
- Hurlin P.J., Queva С., Eisenman R.N. Mnt, a novel Max-interacting protein is coexpressed with Мус in proliferating cells and mediates repression at Мус binding sites // Genes Dev. 1997. V. 11 P. 44−58
- Adhikary S., Eilers M. Transcriptional regulation and transformation by Мус proteins // Nat. Rev. Mol. Cell Biol. 2005. V. 6 P. 635−645
- Blackwell Т.К., Huang J., Ma A., Kretzner L., Alt F.W., Eisenman R.N., Weintraub H. Binding of myc proteins to canonical and noncanonical DNA sequences // Mol. Cell Biol. 1993. V. 13 P. 5216−5224
- Ayer D.E., Eisenman R.N. A switch from Myc. Max to Mad: Max heterocomplexes accompanies monocyte/macrophage differentiation // Genes Dev. 1993. V. 7 P. 21 102 119
- Patel J.H., Loboda A.P., Showe M.K., Showe L.C., McMahon S.B. Analysis of genomic targets reveals complex functions of MYC // Nat. Rev. Cancer 2004. V. 4 P. 562−568
- Izumi H" Molander C., Penn L.Z., Ishisaki A., Kohno K., Funa K. Mechanism for the transcriptional repression by c-Mycon PDGF beta-receptor//J. Cell Sci. 2001. V. 114 P. 1533−1544
- Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Moroy Т., Bartek J., Massague J., Hanel F" Eilers M. Repression of p15INK4b expression by Мус through association with Miz-1 // Nat. Cell Biol. 2001. V. 3 P. 392−399
- Seoane J., Le H.V., Massague J. Мус suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage // Nature 2002. V. 419 P. 729−734
- Datta A., Nag A., Pan W., Hay N., Gartel A.L., Colamonici O., Mori Y., Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Мус // J. Biol. Chem. 2004. V. 279 P. 36 698−36 707
- Qi Y., Gregory M.A., Li Z., Brousal J.P., West K., Hann S.R. p19ARF directly and differentially controls the functions of c-Myc independently of p53 // Nature 2004. V. 431 P. 712−717
- Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., Amati B. Genomic targets of the human c-Myc protein // Genes Dev. 2003. V. 17 P. 1115−1129
- McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2 °F oncoproteins // Cell 1998. V. 94 P. 363−374
- Amati В., Frank S.R., Donjerkovic D., Taubert S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription // Biochim. Biophys. Acta 2001. V. 1471 P. M135-M145
- Park J., Kunjibettu S., McMahon S.B., Cole M.D. The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Мус-dependent oncogenesis // Genes Dev. 2001. V. 15 P. 1619−1624
- Vervoorts J., Luscher-Firzfaff J.M., Rottmann S., Lilischkis R" Walsemann G., Dohmann K., Austen M., Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor СВР // EMBO Rep. 2003. V. 4 P. 484−490
- Wood M.A., McMahon S.B., Cole M.D. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc // Mol. Cell 2000. V. 5 P. 321−330
- Eberhardy S.R., Famham P.J. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism // J. Biol. Chem. 2001. V. 276 P. 4 856 248 571
- Eberhardy S.R., Farnham P.J. Мус recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter // J. Biol. Chem. 2002. V. 277 P. 4 015 640 162
- Felton-Edkins Z.A., Kenneth N.S., Brown T.R., Daly N.L., Gomez-Roman N., Grandori C., Eisenman R.N., White R.J. Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc// Cell Cycle2003. V. 2 P. 181−184
- Gomez-Roman N., Grandori C., Eisenman R.N., White R.J. Direct activation of RNA polymerase III transcription by c-Myc // Nature 2003. V. 421 P. 290−294
- Grummt I. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus//Genes Dev. 2003. V. 17 P. 1691−1702
- Moss T. At the crossroads of growth control- making ribosomal RNA // Curr. Opin. Genet. Dev. 2004. V. 14 P. 210−217
- Grewal S.S., Li L., Orian A., Eisenman R.N., Edgar B.A. Мус-dependent regulation of ribosomal RNA synthesis during Drosophila development // Nat. Cell Biol. 2005. V. 7 P. 295−302
- Wanzel M., Kleine-Kohlbrecher D., Herold S., Hock A., Berns K., Park J., Hemmings В., Eilers M. Akt and 14−3-3eta regulate Miz1 to control cell-cycle arrest after DNA damage // Nat. Cell Biol. 2005. V. 7 P. 30−41
- Gartel A.L., Ye X., Goufman E" Shianov P., Hay N., Najmabadi F" Tyner A.L. Мус represses the p21(WAFl/CIP1) promoter and interacts with Sp1/Sp3 // Proc. Natl. Acad. Sci. U. S. A 2001. V. 98 P. 4510−4515
- Roy A.L., Carruthers C" Gutjahr Т., Roeder R.G. Direct role for Мус in transcription initiation mediated by interactions with TFII-I // Nature 1993. V. 365 P. 359−361
- Shrivastava A., Saleque S., Kalpana G.V., Artandi S., Goff S.P., Calame K. Inhibition of transcriptional regulator Vin-Vang-1 by association with c-Myc // Science 1993. V. 262 P. 1889−1892
- Barsyte-Lovejoy D., Mao D.Y., Penn L.Z. c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism // Oncogene 2004. V. 23 P. 3481−3486
- O’Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression // Nature 2005. V. 435 P. 839−843
- Knoepfler P. S., Cheng P.F., Eisenman R.N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation // Genes Dev. 2002. V. 16 P. 2699−2712
- Kowalczyk A., Filipkowski R.K., Rylski M., Wilczynski G.M., Konopacki F.A., Jaworski J., Ciemerych M.A., Sicinski P., Kaczmarek L. The critical role of cyclin D2 in adult neurogenesis //J. Cell Biol. 2004. V. 167 P. 209−213
- Kenney A.M., Cole M.D., Rowitch D.H. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors // Development 2003. V. 130 P. 15−28
- Kozar K, Ciemerych M.A., Rebel V.I., Shigematsu H., Zagozdzon A., Sicinska E., Geng Y., Yu Q., Bhattacharya S., Branson R.T., Akashi K., Sicinski P. Mouse development and cell proliferation in the absence of D-cyclins // Cell 2004. V. 118 P. 477−491
- Bouchard C., Dittrich O., Kiermaier A., Dohmann K., Menkel A., Eilers M., Luscher B. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent
- TRRAP recruitment and histone acetylation at the cyclin D2 promoter // Genes Dev. 2001. V. 15 P. 2042−2047
- Herald S., Wanzel M., Beuger V., Frohme C., Beul D., Hillukkala Т., Syvaoja J., Saluz H.P., Haenel F., Eilers M. Negative regulation of the mammalian UV response by Мус through association with Miz-1 // Mol. Cell 2002. V. 10 P. 509−521
- Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., la-Favera R., Dang C.V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth // Proc. Natl. Acad. Sci. U. S. A1997. V. 94 P. 6658−6663
- Semenza G.L., Artemov D., Bedi A., Bhujwalla Z., Chiles K., Feldser D., Laughner E., Ravi R., Simons J., Taghavi P., Zhong H. The metabolism of tumours': 70 years later// Novartis. Found. Symp. 2001. V. 240 P. 251−260
- Wu K.J., Polack A., la-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC // Science 1999. V. 283 P. 676−679
- Gregory M.A., Qi Y., Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization // J. Biol. Chem. 2003. V. 278 P. 5 160 651 612
- Welcker M., Orian A., Grim J.E., Eisenman R.N., Clurman B.E. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size // Curr. Biol. 2004. V. 14 P. 18 521 857
- Yada M., Hatakeyama S., Kamura Т., Nishiyama M., Tsunematsu R., Imaki H., Ishida N., Okumura F., Nakayama K., Nakayama K.I. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7 // EMBO J. 2004. V. 23 P. 2116−2125
- Bahram F., von der L.N., Cetinkaya C., Larsson L.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover // Blood 2000. V. 95 P. 2104−2110
- Bouchard C., Marquardt J., Bras A., Medema R.H., Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins // EMBO J. 2004. V. 23 P. 2830−2840
- Watnick R.S., Cheng Y.N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Мус activity to repress thrombospondin-1 expression and increase tumor angiogenesis // Cancer Cell 2003. V. 3 P. 219−231
- Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood Т.О., Land H., Brooks M" Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein // Cell 1992. V. 69 P. 119−128
- Zindy F., Eischen C.M., Randle D.H., Kamijo Т., Cleveland J.L., Sherr C.J., Roussel M.F. Мус signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization // Genes Dev. 1998. V. 12 P. 2424−2433
- Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis // Genes Dev. 1999. V. 13 P. 2658−2669
- Aslanian A., laquinta P.J., Verona R., Lees J.A. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics // Genes Dev. 2004. V. 18 P. 14 131 422
- Juin P., Hueber A.O., Littlewood Т., Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome с release // Genes Dev. 1999. V. 13 P. 1367−1381
- Mitchell K.O., Ricci M.S., Miyashita Т., Dicker D.T., Jin Z., Reed J.C., El-Deiry W.S. Bax is a transcriptional target and mediator of c-myc-induced apoptosis // Cancer Res. 2000. V. 60 P. 6318−6325
- Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor of Myc-induced mouse В cell leukemia // Proc. Natl. Acad. Sci. U. S. A 2004. V. 101 P. 6164−6169
- Eischen C.M., Woo D., Roussel M.F., Cleveland J.L. Apoptosis triggered by Myc-induced suppression of Bcl-X (L) or Bcl-2 is bypassed during lymphomagenesis // Mol. Cell Biol. 2001. V. 21 P. 5063−5070
- Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Мус and triggers carcinogenic progression // Cell 2002. V. 109 P. 321−334
- Karlsson A., Deb-Basu D., Cherry A., Turner S., Ford J., Felsher D.W. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression // Proc. Natl. Acad. Sci. U. S. A 2003. V. 100 P. 9974−9979
- Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages // Mol. Cell 1999. V. 4 P. 199−207
- Arnold I., Watt F.M. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny // Curr. Biol. 2001. V. 11 P. 558−568
- Jonkers J., Berns A. Oncogene addiction: sometimes a temporary slavery // Cancer Cell 2004. V. 6 P. 535−538
- Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis // Proc. Natl. Acad. Sci. U. S. A 1999. V. 96 P. 3940−3944
- Jain M., Arvanitis C" Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC // Science 2002. V. 297 P. 102−104
- Iversen P.L., Arora V., Acker A.J., Mason D.H., Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans // Clin. Cancer Res. 2003. V. 9 P. 2510−2519
- Fest Т., Mougey V., Dalstein V., Hagerty M., Milette D., Silva S" Mai S. c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis II Oncogene 2002. V. 21 P. 2981−2990
- Wechsler D.S., Shelly C.A., Petroff C.A., Dang C.V. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells // Cancer Res. 1997. V. 57 P. 4905−4912
- Chen J., Willingham Т., Margraf L.R., Schreiber-Agus N., DePinho R.A., Nisen P.D. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells // Nat. Med. 1995. V. 1 P. 638−643
- Soucek L., Helmer-Citterich M., Sacco A., Jucker R., Cesareni G., Nasi S. Design and properties of, а Мус derivative that efficiently homodimerizes // Oncogene 1998. V. 17 P. 2463−2472
- Soucek L., Jucker R., Panacchia L., Ricordy R., Tato F., Nasi S. Omomyc, a potential Мус dominant negative, enhances Myc-induced apoptosis // Cancer Res. 2002. V. 62 P. 3507−3510
- Soucek L., Nasi S" Evan G.I. Omomyc expression in skin prevents Myc-induced papillomatosis //Cell Death. Differ. 2004. V. 11 P. 1038−1045
- Kohlhuber F., Hermeking H., Graessmann A., Eick D. Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts II J. Biol. Chem. 1995. V. 270 P. 28 797−28 805
- Draeger L.J., Mullen G.P. Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMRII J. Biol. Chem. 1994. V. 269 P. 1785−1793
- Yin X., Giap C., Lazo J.S., Prochownik E.V. Low molecular weight inhibitors of Myc-Max interaction and function // Oncogene 2003. V. 22 P. 6151−6159
- Mo H., Henriksson M. identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Мус-driven transformation // Proc. Natl. Acad. Sci. U. S. A 2006. V. 103 P. 6344−6349
- Lu X., Pearson A., Lunec J. The MYCN oncoprotein as a drug development target // Cancer Lett. 2003. V. 197 P. 125−130
- Giovannangeli C., Helene C. Triplex-forming molecules for modulation of DNA information processing // Curr. Opin. Mol. Ther. 2000. V. 2 P. 288−296
- Casey B.P., Glazer P.M. Gene targeting via triple-helix formation // Prog. Nucleic Acid Res. Mol. Biol. 2001. V. 67 P. 163−192
- McGuffie E.M., Pacheco 0., Carbone G.M., Catapano C.V. Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells // Cancer Res. 2000. V. 60 P. 3790−3799
- Siddiqui-Jain A., Grand C.L., Bearss D.J., Hurley L.H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription // Proc. Natl. Acad. Sci. U. S. A 2002. V. 99 P. 11 593−11 598
- Lemarteleur Т., Gomez D., Paterski R., Mandine E., Mailliet P., Riou J.F. Stabilization of the c-myc gene promoter quadruplex by specific ligands' inhibitors of telomerase // Biochem. Biophys. Res. Commun. 2004. V. 323 P. 802−808
- Simonsson Т., Henriksson M. c-myc Suppression in Burkitt’s lymphoma cells // Biochem. Biophys. Res. Commun. 2002. V. 290 P. 11−15
- Eder P. S., DeVine R.J., Dagle J.M., Walder J.A. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma И Antisense Res. Dev. 1991. V. 1 P. 141−151
- Lima W.F., Mohan V., Crooke S.T. The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity И J. Biol. Chem. 1997. V. 272 P. 18 191−18 199
- Stahel R.A., Zahgemeister-Wittke U. Antisense oligonucleotides for cancer therapy-an overview // Lung Cancer 2003. V. 41 Suppl 1 P. S81-S88
- Prochownik E.V., Kukowska J., Rodgers C. c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells // Mol. Cell Biol. 1988. V. 8 P. 3683−3695
- Holt J.T., Redner R.L., Nienhuis A.W. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocyte cells and induces differentiation // Mol. Cell Biol. 1988. V. 8 P. 963−973
- Negroni A., Scarpa S., Romeo A., Ferrari S., Modesti A., Raschella G. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line // Cell Growth Differ. 1991. V. 2 P. 511−518
- Smith J.B., Wickstrom E. Inhibition of tumorigenesis in a murine B-cell lymphoma transplant model by c-Myc complementary oligonucleotides //Adv. Exp. Med. Biol. 1998. V. 451 P. 17−22
- Smith J.B., Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model // J. Natl. Cancer Inst. 1998. V. 90 P. 1146−1154
- Huang Y.(Snyder R., Kligshteyn M., Wickstrom E. Prevention of tumor formation in a mouse model of Burkitt’s lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate//Mol. Med. 1995. V. 1 P. 647−658
- Sklar M.D., Prochownik E.V. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc // Cancer Res. 1991. V. 51 P. 2118−2123
- Mizutani Y., Fukumoto M., Bonavida В., Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide // Cancer 1994. V. 74 P. 2546−2554
- Van Waardenburg R.C., Prins J., Meijer C., Uges D.R., De Vries E.G., Mulder N.H. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines//Anticancer Res. 1996. V. 16 P. 1963−1970
- Citro G., D’Agnano I., Leonetti C., Perini R., Bucci В., Zon G., Calabretta В., Zupi G. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice // Cancer Res. 1998. V. 58 P. 283−289
- Knapp D.C., Mata J.E., Reddy M.T., Devi G.R., Iversen P.L. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model // Anticancer Drugs 2003. V. 14 P. 39−47
- Devi G.R., Oldenkamp J.R., London C.A., Iversen P.L. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells // Prostate 2002. V. 53 P. 200−210
- Ricker J.L., Mata J.E., Iversen P.L., Gattone V.H. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD// Kidney Int. 2002. V. 61 Suppl 1 P. 125−131
- Devi G.R., Beer T.M., Corless C.L., Arora V., Weller D.L., Iversen P.L. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors // Clin. Cancer Res. 2005. V. 11 P. 39 303 938
- Henry S.P., Novotny W" Leeds J" Auletta C., Kornbrust D.J. Inhibition of coagulation by a phosphorothioate oligonucleotide // Antisense Nucleic Acid Drug Dev. 1997. V. 7 P. 503−510
- Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides // Biochim. Biophys. Acta 1999. V. 1489 P. 69−84
- Pooga M., Land Т., Bartfai Т., Langel U. PNA oligomers as tools for specific modulation of gene expression // Biomol. Eng 2001. V. 17 P. 183−192
- Pession A., Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors // Curr. Cancer Drug Targets. 2005. V. 5 P. 273−283
- Whitesell L., Rosolen A., Neckers L.M. In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide // Antisense Res. Dev. 1991. V. 1 P. 343−350
- Cheng J., Luo J., Zhang X., Hu J., Hui H., Wang C., Stern A. Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme // Cancer Gene Ther. 2000. V. 7 P. 407−412
- Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans // Nature 1998. V. 391 P. 806−811
- Mello C.C., Conte D., Jr. Revealing the world of RNA interference // Nature 2004. V. 431 P. 338−342
- Zamore P.D., Tuschl Т., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals // Cell 2000. V. 101 P. 25−33
- Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA // Nature 2004. V. 431 P. 343−349
- Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi // Cell 2002. V. 110 P. 563−574
- Hammond S.M. Dicing and slicing: the core machinery of the RNA interference pathway // FEBS Lett. 2005. V. 579 P. 5822−5829
- Lehner В., Williams G., Campbell R.D., Sanderson C.M. Antisense transcripts in the human genome //Trends Genet. 2002. V. 18 P. 63−65
- Carrington J.C., Ambros V. Role of microRNAs in plant and animal development // Science 2003. V. 301 P. 336−338
- Urn L.P., Glasner M.E., Yekta S., Burge C.B., Bartel D.P. Vertebrate microRNA genes // Science 2003. V. 299 P. 1540
- Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function // Cell 2004. V. 116 P. 281−297
- Ambros V. The functions of animal microRNAs // Nature 2004. V. 431 P. 350−355
- Lee Y., Ahn C" Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., Kim V.N. The nuclear RNase III Drosha initiates microRNA processing // Nature 2003. V. 425 P. 415−419
- Mourelatos Z., Dostie J., Paushkin S., Sharma A., Charroux В., Abel L., Rappsilber J., Mann M., Dreyfuss G. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs // Genes Dev. 2002. V. 16 P. 720−728
- Doench J.G., Petersen C.P., Sharp P.A. siRNAs can function as miRNAs // Genes Dev.2003. V. 17 P. 438−442
- Tebes S.J., Kruk P.A. The genesis of RNA interference, its potential clinical applications, and implications in gynecologic cancer // Gynecol. Oncol. 2005. V. 99 P. 736−741
- Fuchs U., mm-Welk C., Borkhardt A. Silencing of disease-related genes by small interfering RNAs // Curr. Mol. Med. 2004. V. 4 P. 507−517
- Pai S.I., Lin Y.Y., Macaes В., Meneshian A., Hung C.F., Wu Т.О. Prospects of RNA interference therapy for cancer // Gene Ther. 2006. V. 13 P. 464−477
- Morris K.V., Rossi J.J. Lentiviral-mediated delivery of siRNAs for antiviral therapy // Gene Ther. 2006. V. 13 P. 553−558
- Oates A.C., Bruce A.E., Ho R.K. Too much interference: injection of double-stranded RNA has nonspecific effects in the zebrafish embryo // Dev. Biol. 2000. V. 224 P. 20−28
- Elbashir S.M., Harborth J., Lendeckel W" Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells // Nature 2001. V. 411 P. 494−498
- Hohjoh H. Enhancement of RNAi activity by improved siRNA duplexes II FEBS Lett.2004. V. 557 P. 193−198
- Sioud M. Therapeutic siRNAs // Trends Pharmacol. Sci. 2004. V. 25 P. 22−28
- Ui-Tei K., Naito Y., Takahashi F., Haraguchi Т., Ohki-Hamazaki H., Juni A., Ueda R., Saigo K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference II Nucleic Acids Res. 2004. V. 32 P. 936−948
- Dykxhoorn D.M., Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic II Annu. Rev. Med. 2005. V. 56 P. 401−423
- Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A., Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo // Biochem. Biophys. Res. Commun. 2002. V. 296 P. 1000−1004
- Hutvagner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex II Science 2002. V. 297 P. 2056−2060
- Amarzguioui M., Holen Т., Babaie E., Prydz H. Tolerance for mutations and chemical modifications in a siRNA//Nucleic Acids Res. 2003. V. 31 P. 589−595
- Braasch D.A., Jensen S., Liu Y., Kaur K., Arar K., White M.A., Corey D.R. RNA interference in mammalian cells by chemically-modified RNA // Biochemistry 2003. V. 42 P. 7967−7975
- Dorsett Y., Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics II Nat. Rev. Drug Discov. 2004. V. 3 P. 318−329
- Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells // Nat. Genet. 2003. V. 34 P. 263−264
- Sledz С.A., Holko M., de Veer M.J., Silverman R.H., Williams B.R. Activation of the interferon system by short-interfering RNAs // Nat. Cell Biol. 2003. V. 5 P. 834−839
- Persengiev S.P., Zhu X., Green M.R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs) // RNA. 2004. V. 10 P. 12−18
- Heidel J.D., Hu S., Liu X.F., Triche T.J., Davis M.E. Lack of interferon response in animals to naked siRNAs // Nat. Biotechnol. 2004. V. 22 P. 1579−1582
- Kariko K., Bhuyan P., Capodici J., Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3 // J. Immunol. 2004. V. 172 P. 6545−6549
- Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization // J. Mol. Biol. 2005. V. 348 P. 1079−1090
- Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA // Nat. Biotechnol. 2005. V. 23 P. 457−462
- Fedorov Y., King A., Anderson E., Karpilow J., Ilsley D., Marshall W., Khvorova A. Different delivery methods-different expression profiles // Nat. Methods 2005. V. 2 P. 241
- Hosono Т., Mizuguchi H., Katayama K., Xu Z.L., Sakurai F., Ishii-Watabe A., Kawabata K., Yamaguchi Т., Nakagawa S., Mayumi Т., Hayakawa T. Adenovirus vector-mediated doxycycline-inducible RNA interference // Hum. Gene Ther. 2004. V. 15 P. 813−819
- Wang Y.H., Liu S., Zhang G" Zhou C.Q., Zhu H.X., Zhou X.B., Quan L.P., Bai J.F., Xu N.Z. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo II Breast Cancer Res. 2005. V. 7 P. R220-R228
- Stevenson M. Therapeutic potential of RNA interference II N. Engl. J. Med. 2004. V. 351 P. 1772−1777
- Demeterco C., Itkin-Ansari P., Tyrberg В., Ford L.P., Jarvis R.A., Levine F. c-Myc controls proliferation versus differentiation in human pancreatic endocrine cells // J. Clin. Endocrinol. Metab 2002. V. 87 P. 3475−3485
- Gao X., Wang H., Sairenji T. Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells // J. Virol. 2004. V. 78 P. 11 798−11 806
- Shen L., Zhang C., Ambrus J.L., Wang J.H. Silencing of human c-myc oncogene expression by poly-DNP-RNA // Oligonucleotides. 2005. V. 15 P. 23−35
- Chen X., Shen L., Wang J.H. Poly-2'-DNP-RNAs with enhanced efficacy for inhibiting cancer cell growth // Oligonucleotides. 2004. V. 14 P. 90−99
- Aronin N. Target selectivity in mRNA silencing // Gene Ther. 2006. V. 13 P. 509−516
- Li X., Stuckert P., Bosch I., Marks J.D., Marasco W.A. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells // Cancer Gene Ther. 2001. V. 8 P. 555−565
- Shang Y., Baumrucker C.R., Green M.H. c-Myc is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells // J. Biol. Chem. 1998. V. 273 P. 30 608−30 613
- Lampson G.P., Tytell A.A., Field A.K., Nemes M.M., Hilleman M.R. Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum // Proc. Natl. Acad. Sci. U. S. A 1967. V. 58 P. 782−789
- Samuel C.E. Antiviral actions of interferons // Clin. Microbiol. Rev. 2001. V. 14 P. 778 809, table
- Castelli J.C., Hassel B.A., Wood K.A., Li X.L., Amemiya K., Dalakas M.C., Torrence P.F., Youle R.J. A study of the interferon antiviral mechanism: apoptosis activation by the 2−5A system //J. Exp. Med. 1997. V. 186 P. 967−972
- Clemens M.J. PKR-a protein kinase regulated by double-stranded RNA // Int. J. Biochem. Cell Biol. 1997. V. 29 P. 945−949
- Underbill D.M., Ozinsky A. Toll-like receptors: key mediators of microbe detection // Curr. Opin. Immunol. 2002. V. 14 P. 103−110
- Meurs E., Chong K., Galabru J., Thomas N.S., Kerr I.M., Williams B.R., Hovanessian A.G. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon // Cell 1990. V. 62 P. 379−390
- Samuel C.E. The elF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans // J. Biol. Chem. 1993. V. 268 P. 7603−7606
- Manche L., Green S.R., Schmedt C., Mathews M.B. Interactions between double-stranded RNA regulators and the protein kinase DAI // Mol. Cell Biol. 1992. V. 12 P. 5238−5248
- Spanggord R.J., Vuyisich M., Seal P.A. Identification of binding sites for both dsRBMs of PKR on kinase-activating and kinase-inhibiting RNA ligands // Biochemistry 2002. V. 41 P. 4511−4520
- Kumar A., Haque J., Lacoste J., Hiscott J., Williams B.R. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa В by phosphorylating I kappa В// Proc. Natl. Acad. Sci. U. S. A 1994. V. 91 P. 6288−6292
- Xu Z., Williams B.R. The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR // Mol. Cell Biol. 2000. V. 20 P. 5285−5299
- Langland J.O., Kao P.N., Jacobs B.L. Nuclear factor-90 of activated T-cells: A double-stranded RNA-binding protein and substrate for the double-stranded RNA-dependent protein kinase, PKR // Biochemistry 1999. V. 38 P. 6361−6368
- Clemens M.J. Does protein phosphorylation play a role in translational control by eukaryotic aminoacyl-tRNA synthetases? // Trends Biochem. Sci. 1990. V. 15 P. 172 175
- Zandi E., Karin M. Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex// Mol. Cell Biol. 1999. V. 19 P. 4547−4551
- Delhase M., Hayakawa M" Chen Y., Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation // Science 1999. V. 284 P. 309−313
- Zandi E., Karin M. Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex// Mol. Cell Biol. 1999. V. 19 P. 4547−4551
- Zamanian-Daryoush M., Mogensen Т.Н., DiDonato J.A., Williams B.R. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase // Mol. Cell Biol. 2000. V. 20 P. 12 781 290
- Cuddihy A.R., Li S., Tam N.W., Wong A.H., Taya Y" Abraham N., Bell J.C., Koromilas A.E. Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53 // Mol. Cell Biol. 1999. V. 19 P. 2475−2484
- Donze O., Dostie J., Sonenberg N. Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis and fas receptor expression // Virology 1999. V. 256 P. 322−329
- Goh K.C., deVeer M.J., Williams B.R. The protein kinase PKR is required for p38 МАРК activation and the innate immune response to bacterial endotoxin // EMBO J. 2000. V. 19 P. 4292−4297
- Li G., Xiang Y., Sabapathy K., Silverman R.H. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase // J. Biol. Chem. 2004. V. 279 P. 1123−1131
- Balachandran S., Kim C.N., Yeh W.C., Мак T.W., Bhalla K., Barber G.N. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling // EMBO J. 1998. V. 17 P. 6888−6902
- Gil J., Garcia M.A., Esteban M. Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance // FEBS Lett. 2002. V. 529 P. 249 255
- Kumar M., Carmichael G.G. Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes II Microbiol. Mol. Biol. Rev. 1998. V. 62 P. 1415−1434
- Dong В., Silverman R.H. 2−5A-dependent RNase molecules dimerize during activation by 2−5A // J. Biol. Chem. 1995. V. 270 P. 4133−4137
- Li X.L., Blackford J.A., Hassel B.A. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection // J. Virol. 1998. V. 72 P. 2752−2759
- Akira S., Takeda K. Toll-like receptor signalling // Nat. Rev. Immunol. 2004. V. 4 P. 499 511
- Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 // Nature 2001. V. 413 P. 732 738
- Crozat K, Beutler B. TLR7: A new sensor of viral infection // Proc. Natl. Acad. Sci. U. S. A 2004. V. 101 P. 6835−6836
- Hemmi H., Takeuchi O., Kawai Т., Kaisho Т., Sato S" Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA // Nature 2000. V. 408 P. 740−745
- Rehli M. Of mice and men: species variations of Toll-like receptor expression // Trends Immunol. 2002. V. 23 P. 375−378
- Matsumoto M., Kikkawa S., Kohase M., Miyake K., Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling // Biochem. Biophys. Res. Commun. 2002. V. 293 P. 13 641 369
- Kariko K., Ni H., Capodici J" Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3 // J. Biol. Chem. 2004. V. 279 P. 12 542−12 550
- Vogel S.N., Fitzgerald K.A., Fenton M.J. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression // Mol. Interv. 2003. V. 3 P. 466−477
- Sen G.C., Sarkar S.N. Transcriptional signaling by double-stranded RNA: role of TLR3 // Cytokine Growth Factor Rev. 2005. V. 16 P. 1−14
- Thale C., Kiderien A.F. Sources of interferon-gamma (IFN-gamma) in early immune response to Listeria monocytogenes // Immunobiology 2005. V. 210 P. 673−683
- Samuel M.A., Diamond M.S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival // J. Virol. 2005. V. 79 P. 13 350−13 361
- Schroder K., Hertzog P.J., Ravasi Т., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions // J. Leukoc. Biol. 2004. V. 75 P. 163−189
- Munoz-Jordan J.L., Sanchez-Burgos G.G., Laurent-Rolle M., Garcia-Sastre A. Inhibition of interferon signaling by dengue virus // Proc. Natl. Acad. Sci. U. S. A 2003. V. 100 P. 14 333−14 338
- Basler C.F., Garcia-Sastre A. Viruses and the type I interferon antiviral system: induction and evasion // Int. Rev. Immunol. 2002. V. 21 P. 305−337
- Boudny V., Kovarik J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription // Neoplasma 2002. V. 49 P. 349−355
- Bach E.A., Aguet M., Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling // Annu. Rev. Immunol. 1997. V. 15 P. 563−591
- Einat M., Resnitzky D., Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest// Nature 1985. V. 313 P. 597−600
- Yarden A., Kimchi A. Tumor necrosis factor reduces c-myc expression and cooperates with interferon-gamma in HeLa cells // Science 1986. V. 234 P. 1419−1421
- Sangfelt O., Erickson S., Grander D. Mechanisms of interferon-induced cell cycle arrest // Front Biosci. 2000. V. 5 P. D479-D487
- Wada R.K., Pai D.S., Huang J., Yamashiro J.M., Sidell N. Interferon-gamma and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action // Cancer Lett. 1997. V. 121 P. 181−188
- Новиков В.И. Иммунотерапия при злокачественных новообразованиях // М. 1997.
- Damha M.J., Ogilvie К.К. Oligoribonucleotide synthesis. The silyl-phosphoramidite method // Methods Mol. Biol. 1993. V. 20 P. 81−114
- Donis-Keller H., Maxam A.M., Gilbert W. Mapping adenines, guanines, and pyrimidines in RNA // Nucleic Acids Res. 1977. V. 4 P. 2527−2538
- Milligan J.F., Groebe D.R., Witherell G.W., Uhlenbeck O.C. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates // Nucleic Acids Res. 1987. V. 15 P. 8783−8798
- England Т.Е., Bruce A.G., Uhlenbeck O.C. Specific labeling of 3' termini of RNA with T4 RNA ligase // Methods Enzymol. 1980. V. 65 P. 65−74
- Chattopadhyay N., Kher R., Godbole M. Inexpensive SDS/phenol method for RNA extraction from tissues II Biotechniques 1993. V. 15 P. 24−26
- Siebert P.D. Quantitative RT-PCR. Methods and Applications. Book 3. // USA: Clontech Laboratories Inc. 1993.
- Cobb B.D., Clarkson J.M. A simple procedure for optimising the polymerase chain reaction (PCR) using modified Taguchi methods // Nucleic Acids Res. 1994. V. 22 P. 3801−3805
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 // Nature 1970. V. 227 P. 680−685
- Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing // Cancer Res. 1987. V. 47 P. 936−942
- Proudnikov D., Mirzabekov A. Chemical methods of DNA and RNA fluorescent labeling II Nucleic Acids Res. 1996. V. 24 P. 4535−4542
- Rosenbaum H., Webb E., Adams J.M., Cory S., Harris A.W. N-myc transgene promotes В lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc // EMBO J. 1989. V. 8 P. 749−755
- Dildrop R., Ma A., Zimmerman K., Hsu E., Tesfaye A., DePinho R., Alt F.W. IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression // EMBO J. 1989. V. 8 P. 1121−1128
- Du Q., Thonberg H., Wang J., Wahlestedt C., Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites // Nucleic Acids Res. 2005. V. 33 P. 1671−1677
- Cao M., Ren H., Pan X., Pan W., Qi Z.T. Inhibition of EGFP expression by siRNA in EGFP-stably expressing Huh-7 cells//J. Virol. Methods2004. V. 119 P. 189−194
- Amarzguioui M., Rossi J.J., Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi IIFEBS Lett. 2005. V. 579 P. 5974−5981
- Poliseno L., Mercatanti A., Citti L., Rainaldi G. RNA-based drugs: from RNA interference to short interfering RNAs // Curr. Pharm. Biotechnol. 2004. V. 5 P. 361−368
- Donze O., Picard D. RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase // Nucleic Acids Res. 2002. V. 30 P. e46
- Sohail M., Doran G., Riedemann J., Macaulay V., Southern E.M. A simple and cost-effective method for producing small interfering RNAs with high efficacy // Nucleic Acids Res. 2003. V. 31 P. e38
- Fagot D., Buquet-Fagot C., Lallemand F., Mester J. Antiproliferative effects of sodium butyrate in adriamycin-sensitive and -resistant human cancer cell lines // Anticancer Drugs 1994. V. 5 P. 548−556
- Feo S., Di L.C., Jones Т., Read M., Fried M. The DNA region around the c-myc gene and its amplification in human tumour cell lines // Oncogene 1994. V. 9 P. 955−961
- Hemmi H., Yamada K., Yoon U.H., Kato M., Taniguchi F., Tsuchida Y., Shimatake H. Coexpression of the myc gene family members in human neuroblastoma cell lines // Biochem. Mol. Biol. Int. 1995. V. 36 P. 1135−1141
- Kim D.H., Longo M., Han Y., Lundberg P., Cantin E., Rossi J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase // Nat. Biotechnol. 2004. V. 22 P. 321−325
- Matsumoto M., Funami K., Oshiumi H., Seya T. Toll-like receptor 3: a link between tolllike receptor, interferon and viruses // Microbiol. Immunol. 2004. V. 48 P. 147−154
- Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference // Nature 2001. V. 409 P. 363−366
- Rosenblatt M.N., Burns J.R., Duncan V.E., Hughes J.A. Infection of the macrophage cell line NR8383 with Mycobacterium tuberculosis (H37Ra) leads to an increase in oligodeoxynucleotide accumulation // Antisense Nucleic Acid Drug Dev. 2000. V. 10 P. 1−9
- Galderisi U., Di B.G., Cipollaro M., Peluso G., Cascino A., Cotrufo R., Melone M.A. Differentiation and apoptosis of neuroblastoma ceils: role of N-myc gene product // J. Cell Biochem. 1999. V. 73 P. 97−105
- Amy CM, Bartholomew J.C. Regulation of N-myc transcript stability in human neuroblastoma and retinoblastoma cells // Cancer Res. 1987. V. 47 P. 6310−6314
- Shimazaki Т., Honda M., Kaneko S., Kobayashi K. Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein II Hepatology 2002. V. 35 P. 199−208
- Kaempfer R. RNA sensors: novel regulators of gene expression // EMBO Rep. 2003. V. 4 P. 1043−1047